Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TB-840 in Healthy Subjects
NCT05045534Phase 1Completed
- Sponsor
- TheraSid Bioscience
- Start
- Sep 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TB-840 in Nonalcoholic steatohepatitis (NASH) (11 cohorts), sponsored by TheraSid Bioscience. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v5.03 up to 14 days. Started Sep 2021; status: completed.
02
Drugs
TB-840
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05045534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05045534.